Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.01
-6.5%
$4.89
$3.42
$9.35
$225.42M1.632.56 million shs1.02 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$28.14
-3.0%
$30.02
$27.28
$42.29
$904.19M0.76437,860 shs384,608 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$18.69
-6.7%
$21.03
$15.96
$30.03
$915.89M1.03280,139 shs516,094 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$12.79
-8.6%
$19.85
$12.56
$40.84
$770.69M3.05567,896 shs1.64 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-6.53%-9.48%-20.28%-14.68%-44.38%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
-3.03%-5.28%-1.16%-4.64%-28.67%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-6.69%-11.30%-12.05%-23.46%+0.54%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-8.58%-28.71%-34.31%-47.47%-63.10%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2761 of 5 stars
0.02.00.00.01.30.80.6
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.0052 of 5 stars
3.41.00.03.03.30.82.5
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.4599 of 5 stars
3.61.00.00.03.24.20.0
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
1.9801 of 5 stars
3.60.00.00.03.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.80
Moderate Buy$43.6054.94% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.20
Buy$38.75107.33% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.13
Buy$50.33293.54% Upside

Current Analyst Ratings Breakdown

Latest ACB, SYRE, ELVN, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/24/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
3/21/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $39.00
3/18/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$27.00
2/18/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/5/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Atb Cap Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
2/4/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$37.00 ➝ $36.00
1/13/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$65.00
1/10/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
1/10/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$46.00
(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.70$0.15 per share26.35$8.18 per share0.49
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.43$10.20 per share2.76$5.99 per share4.70
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$5.97 per shareN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K865.94N/AN/A($0.22) per share-58.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0580.229.11N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$48.15M$1.8612.134.67N/A14.78%104.67%18.38%5/8/2025 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$338.79M-$4.23N/AN/AN/AN/A-210.01%-44.40%5/8/2025 (Estimated)

Latest ACB, SYRE, ELVN, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/13/2025Q4 2024
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.53-$0.46+$0.07-$0.46N/A$0.03 million
2/27/2025Q4 2024
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.54$1.63+$0.09$0.36$179.68 million$181.95 million
2/27/2025Q4 2024
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.89-$0.81+$0.08-$0.81$2.10 millionN/A
2/5/2025Q3 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$0.09$0.06+$0.15$0.41$80.01 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.43
0.97
0.88
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
17.44
17.44
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
7.32
7.32

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.98%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
29.20%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
6.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million30.97 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5049.00 million34.59 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
10060.26 million48.24 millionOptionable

Recent News About These Companies

Spyre Therapeutics initiated with an Outperform at Wolfe Research

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.01 -0.28 (-6.53%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$4.03 +0.02 (+0.60%)
As of 04/4/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$28.14 -0.88 (-3.03%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$28.12 -0.02 (-0.05%)
As of 04/4/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$18.69 -1.34 (-6.69%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$18.68 -0.01 (-0.05%)
As of 04/4/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$12.79 -1.20 (-8.58%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$12.75 -0.04 (-0.31%)
As of 04/4/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.